Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin 53226

18 studies enrolling now · 55 studies all time

What they study most

AL Amyloidosis, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Adult CML, Advanced Breast Cancer, Advanced Cancer, Aggressive Fibromatosis, B-cell Lymphoma, Brain Metastases

Studies at this site

• A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer — Recruiting now
• Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer — Recruiting now
• Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma — Recruiting now
• Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique — Recruiting now
• Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration — Recruiting now
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
• Ivosidenib as Post-HSCT Maintenance for AML — Recruiting now
• Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses — Recruiting now
• Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence — Recruiting now
• Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma — Recruiting now
• Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome — Recruiting now
• Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) — Recruiting now
• Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer — Recruiting now
• Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency — Recruiting now
• Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X) — Recruiting now
• Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation — Recruiting now
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer — Recruiting now
• Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase — Running, not enrolling
• Elimination of Minimal Residual Disease After Transplant — Running, not enrolling
• Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis — Running, not enrolling
• Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma — Running, not enrolling
• Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma — Starting soon
• A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) — Completed
• Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors — Running, not enrolling
• Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Running, not enrolling
• Inhibition of Oral Tumorigenesis by Antitumor B — Completed
• A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML — Stopped early
• De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis — Running, not enrolling
• Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) — Running, not enrolling
• Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation — Completed
• A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery — Running, not enrolling
• Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma — Running, not enrolling
• Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies — Running, not enrolling
• Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors — Completed
• XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia — Stopped early
• Study of Magrolimab Combinations in Participants With Myeloid Malignancies — Stopped early
• Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) — Completed
• Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma — Stopped early
• Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Withdrawn before enrolling
• Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) — Status unconfirmed
• Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) — Stopped early
• Study of GNX102 in Patients With Advanced Solid Tumors — Stopped early
• Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma — Completed
• Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Completed
• G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer — Completed
• Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis — Status unconfirmed
• Feasibility of Using Ultrasound to Track Respiration Motion — Completed
• Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Completed
• Topical Antisepsis in Head and Neck Cancer Surgery — Completed
• Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer — Completed